Search results
Geron shares surge after U.S. FDA approves blood disorder drug
WHTC 1450 Holland· 12 hours ago(Reuters) - Shares of Geron rose almost 16% on Friday before market, a day after getting its first...
The 5 Stocks Defining 'The Year Of The Dividend' In 2024
Benzinga via Yahoo Finance· 4 days agoReinvested stock dividends have significantly influenced the total return of the S&P 500 since 1927....
Sana Al Sukhun, MD, on Metastatic Breast Cancer Treatment in Lower-Income Settings
MedPage Today· 3 days agoTreatment guidelines for patients with metastatic breast cancer often recommend tests, drugs, and...
2024 is being called ‘the year of the dividend.’ These 5 stocks keep on giving.
MarketWatch via Yahoo Finance· 6 days agoGetty Images/iStockphoto - Stock dividends are anything but boring — they’re responsible for 36% of...
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Benzinga via Yahoo Finance· 1 day agoThursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of...
Bristol’s $250,000 Pill Slows Lung Cancer Growth by Seven Weeks
Bloomberg· 6 days agoHave a confidential tip for our reporters? A Bristol Myers Squibb Co. lung cancer treatment delayed...
Geron surges after winning first US FDA approval for blood disorder drug
AOL· 12 hours ago(Reuters) -Shares of Geron surged more than 20% on Friday, a day after the company gained its first approval from the U.S. Food and Drug Administration for its blood disorder drug. The health ...
Replimune up 30% on results for RP1 combo in melanoma (NASDAQ:REPL)
Seeking Alpha· 1 day agoReplimmune Group reports positive results in melanoma patients who failed on PD-1 inhibitors,...
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Zacks via Yahoo Finance· 3 days agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Benzinga· 1 day agoThursday, Replimune Group Inc REPL released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. Bristol-Myers Squibb Co’ ...